Author

L. J. Stevens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:multiome· 1 Organism:virus· 1

Frequent Co-Authors

A. J. Pruijssers· 3 shared M. R. Denison· 3 shared X. Lu· 3 shared A. S. George· 2 shared D. P. Porter· 2 shared D. R. Martinez· 2 shared J. D. Chappell· 2 shared J. Gribble· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. J. Pruijssers

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir

L. J. Stevens, A. J. Pruijssers, H. W. Lee, C. J. Gordon, E. P. Tchesnokov, J. Gribble, A. S. George, T. M. Hughes, X. Lu, J. Li, J. K. Perry, D. P. Porter, T. Cihlar, T. P. Sheahan, R. S. Baric, , M. R. Denison

This study identifies distinct mutations in SARS-CoV-2's RdRp that confer remdesivir resistance, showing their biochemical mechanisms and transferability to other coronaviruses.

bioRxiv · Jan 25, 2022 · PreprintMicrobiology

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

K. S. Corbett, D. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schafer, C. T. Ziwawo, A. T. DiPiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, , Wang

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

bioRxiv · Jun 11, 2020Immunology

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

A. J. Pruijssers, A. S. George, A. Schäfer, S. R. Leist, L. E. Gralinski, K. H. Dinnon, B. L. Yount, M. L. Agostini, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, K. L. Gully, D. R. Martinez, A. J. Brown, , T. P. Sheahan

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

bioRxiv · Apr 27, 2020Microbiology

The coronavirus proofreading exoribonuclease mediates extensive viral recombination

J. Gribble, A. J. Pruijssers, M. L. Agostini, J. Anderson-Daniels, J. D. Chappell, X. Lu, L. J. Stevens, A. L. Routh, M. R. Denison

This study shows that the coronavirus proofreading exoribonuclease nsp14-ExoN is essential for RNA recombination and generates defective viral genomes.

bioRxiv · Apr 23, 2020Microbiology